ADIPOR2 and metabolic dysfunction-associated steatohepatitis: Rosiglitazone treatment for 8 weeks improves the histological lesions in liver of nonalcoholic steatohepatitis rats, increases mRNA and protein expressions of AdipoR1 and AdipoR2 in liver and visceral fat, with down-regulation of the two receptors in muscle [30].